{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alaunos Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"TCRT"},"Address":{"label":"Address","value":"8030 EL RIO STREET,NAVY YARD PLAZA, HOUSTON, Texas, 77054, United States"},"Phone":{"label":"Phone","value":"+1 346 355-4099"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ziopharm Oncology Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Ziopharm Oncology Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Ziopharm Oncology Inc. ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad."},"CompanyUrl":{"label":"Company Url","value":"https://www.alaunos.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dale Curtis Hogue","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}